300003 乐普医疗
已收盘 01-09 15:00:00
资讯
新帖
简况
1月8日乐普医疗涨5.99%，汇添富民营活力混合基金重仓该股
证券之星 · 01-08
1月8日乐普医疗涨5.99%，汇添富民营活力混合基金重仓该股
国金证券：给予乐普医疗增持评级，目标价21.0元
证券之星 · 01-07
国金证券：给予乐普医疗增持评级，目标价21.0元
乐普医疗（300003）披露2025年第四季度可转换公司债券转股情况，1月5日股价上涨19.99%
证券之星 · 01-05
乐普医疗（300003）披露2025年第四季度可转换公司债券转股情况，1月5日股价上涨19.99%
乐普医疗涨19.99%，中国银河二个月前给出“买入”评级
证券之星 · 01-05
乐普医疗涨19.99%，中国银河二个月前给出“买入”评级
创新药概念表现活跃 乐普医疗强势涨停
证券之星 · 01-05
创新药概念表现活跃 乐普医疗强势涨停
异动快报：乐普医疗（300003）1月5日10点45分触及涨停板
证券之星 · 01-05
异动快报：乐普医疗（300003）1月5日10点45分触及涨停板
童颜针价格战白热化 乐普医疗靠医美“救场”能否挽救传统业务颓势？
华夏时报网 · 2025-12-19
童颜针价格战白热化 乐普医疗靠医美“救场”能否挽救传统业务颓势？
乐普医疗：童颜针与水光针实现营业收入8613.67万元
证券之星 · 2025-12-16
乐普医疗：童颜针与水光针实现营业收入8613.67万元
乐普医疗：不向下修正“乐普转2”转股价格
证券之星 · 2025-12-16
乐普医疗：不向下修正“乐普转2”转股价格
乐普医疗：截至目前未持有君实生物股份
证券之星 · 2025-12-16
乐普医疗：截至目前未持有君实生物股份
乐普医疗董事会决定不向下修正“乐普转2”转股价格
中金财经 · 2025-12-05
乐普医疗董事会决定不向下修正“乐普转2”转股价格
乐普医疗（300003）披露关于预计触发乐普转2转股价格向下修正条件的提示性公告，12月1日股价上涨0.38%
证券之星 · 2025-12-01
乐普医疗（300003）披露关于预计触发乐普转2转股价格向下修正条件的提示性公告，12月1日股价上涨0.38%
乐普生物-B(02157)与乐普医疗订立CDMO服务框架协议
智通财经 · 2025-11-28
乐普生物-B(02157)与乐普医疗订立CDMO服务框架协议
乐普医疗（300003）披露召开2025年第二次临时股东大会提示性公告，11月05日股价上涨3.35%
证券之星 · 2025-11-05
乐普医疗（300003）披露召开2025年第二次临时股东大会提示性公告，11月05日股价上涨3.35%
乐普医疗跌4.95% 中国银河等3券商年内高点唱多
中金财经 · 2025-11-04
乐普医疗跌4.95% 中国银河等3券商年内高点唱多
乐普医疗(300003.SZ)：可充电植入式脑深部神经刺激器系统产品获注册批准
智通财经 · 2025-11-04
乐普医疗(300003.SZ)：可充电植入式脑深部神经刺激器系统产品获注册批准
乐普医疗（300003）披露可转债转股价格调整公告，11月03日股价上涨0.28%
证券之星 · 2025-11-03
乐普医疗（300003）披露可转债转股价格调整公告，11月03日股价上涨0.28%
乐普医疗公布国际专利申请：“一种PPG信号血糖预测模型的处理方法和装置”
证券之星 · 2025-11-01
乐普医疗公布国际专利申请：“一种PPG信号血糖预测模型的处理方法和装置”
乐普医疗最新公告：子公司与丹麦Sidera签署授权许可协议获9.99%股权及累计不超过10.1亿美元里程碑付款
证券之星 · 2025-10-31
乐普医疗最新公告：子公司与丹麦Sidera签署授权许可协议获9.99%股权及累计不超过10.1亿美元里程碑付款
乐普医疗：医美产品进展及布局影响
证券之星 · 2025-10-28
乐普医疗：医美产品进展及布局影响
加载更多
公司概况
公司名称：
乐普(北京)医疗器械股份有限公司
所属行业：
专用设备制造业
上市日期：
2009-10-30
主营业务：
乐普(北京)医疗器械股份有限公司的主营业务是提供心血管疾病领域全生命周期的整体解决方案。公司的主要产品是医疗器械、药品、医疗服务、健康管理。截至报告期末，公司累计申请专利2,374项，国家药品监督管理局注册批准的II、III类医疗器械注册证687个，美国FDA认证34项，欧盟CE认证214项。
发行价格：
29.00
{"stockData":{"symbol":"300003","market":"SZ","secType":"STK","nameCN":"乐普医疗","latestPrice":19.45,"timestamp":1767942201000,"preClose":19.64,"halted":0,"volume":115367049,"delay":0,"changeRate":-0.0097,"floatShares":1579000000,"shares":1843000000,"eps":0.2313,"marketStatus":"已收盘","change":-0.19,"latestTime":"01-09 15:00:00","open":19.45,"high":19.59,"low":18.75,"amount":2224000000,"amplitude":0.0428,"askPrice":19.46,"askSize":888,"bidPrice":19.45,"bidSize":2418,"shortable":0,"etf":0,"ttmEps":0.2313,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1768181400000},"marketStatusCode":5,"adr":0,"adjPreClose":19.64,"symbolType":"stock","openAndCloseTimeList":[[1767922200000,1767929400000],[1767934800000,1767942000000]],"highLimit":21.6,"lowLimit":17.68,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":1843396544,"isCdr":false,"pbRate":2.29,"roa":"--","peRate":84.089927,"roe":"6.25%","epsLYR":0.1336,"committee":0.47785,"marketValue":35854000000,"turnoverRate":0.0731,"status":1,"floatMarketCap":30709000000},"requestUrl":"/m/hq/s/300003","defaultTab":"news","newsList":[{"id":"2601603356","title":"1月8日乐普医疗涨5.99%，汇添富民营活力混合基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2601603356","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601603356?lang=zh_cn&edition=full","pubTime":"2026-01-08 15:38","pubTimestamp":1767857915,"startTime":"0","endTime":"0","summary":"证券之星消息，1月8日乐普医疗涨5.99%，收盘报19.64元，换手率11.04%，成交量174.32万手，成交额33.91亿元。根据2025基金Q3季报公募基金重仓股数据，重仓该股的公募基金共58家，其中持有数量最多的公募基金为汇添富基金的汇添富民营活力混合。汇添富民营活力混合目前规模为33.48亿元，最新净值7.543，较上一交易日上涨0.96%，近一年上涨79.42%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010800019304.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0251","300003","BK0113","BK0188","BK0028","BK0201","BK0114","BK0042","BK0196"],"gpt_icon":0},{"id":"2601882603","title":"国金证券：给予乐普医疗增持评级，目标价21.0元","url":"https://stock-news.laohu8.com/highlight/detail?id=2601882603","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601882603?lang=zh_cn&edition=full","pubTime":"2026-01-07 12:55","pubTimestamp":1767761714,"startTime":"0","endTime":"0","summary":"国金证券股份有限公司赵中平,杨欣,杨雨钦近期对乐普医疗进行研究并发布了研究报告《严肃医疗强背景，医美筑新增长极》，给予乐普医疗增持评级，目标价21.0元。最新盈利预测明细如下：该股最近90天内共有10家机构给出评级，买入评级9家，增持评级1家；过去90天内机构目标均价为22.38。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010700016815.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300003"],"gpt_icon":0},{"id":"2601882540","title":"乐普医疗（300003）披露2025年第四季度可转换公司债券转股情况，1月5日股价上涨19.99%","url":"https://stock-news.laohu8.com/highlight/detail?id=2601882540","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601882540?lang=zh_cn&edition=full","pubTime":"2026-01-05 22:02","pubTimestamp":1767621724,"startTime":"0","endTime":"0","summary":"截至2026年1月5日收盘，乐普医疗报收于18.97元，较前一交易日上涨19.99%，最新总市值为349.69亿元。该股当日开盘16.55元，最高18.97元，最低16.55元，成交额达26.13亿元，换手率为9.07%。近日，乐普（北京）医疗器械股份有限公司发布关于2025年第四季度可转换公司债券转股情况的公告。公告显示，2025年第四季度期间，“乐普转2”可转换公司债券转股减少50张，转股数量为177股。同时，公司披露了股份变动情况，总股本由1,880,612,067股变更为1,843,396,544股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010500039482.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0188","300003","BK0114","BK0113","BK0201","BK0251","BK0196","BK0042"],"gpt_icon":0},{"id":"2601889006","title":"乐普医疗涨19.99%，中国银河二个月前给出“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2601889006","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601889006?lang=zh_cn&edition=full","pubTime":"2026-01-05 15:43","pubTimestamp":1767599029,"startTime":"0","endTime":"0","summary":"今日乐普医疗涨19.99%，收盘报18.97元。2025年10月29日，中国银河研究员程培,孟熙发布了对乐普医疗的研报《2025年三季报业绩点评：医美放量超预期，创新管线稳步推进》，该研报对乐普医疗给出“买入”评级。研报中预测公司2025-2027年归母净利润至12.00/15.43/19.50亿元，同比增长385.80%、28.65%、26.34%，EPS分别为0.64、0.82、1.04元，当前股价对应2025-2027年PE 28/22/17倍，维持“推荐”评级。证券之星数据中心根据近三年发布的研报数据计算，该研报作者对此股的盈利预测准确度为9.02%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010500015744.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300003","601881"],"gpt_icon":0},{"id":"2601077915","title":"创新药概念表现活跃 乐普医疗强势涨停","url":"https://stock-news.laohu8.com/highlight/detail?id=2601077915","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601077915?lang=zh_cn&edition=full","pubTime":"2026-01-05 13:12","pubTimestamp":1767589956,"startTime":"0","endTime":"0","summary":"1月5日，创新药概念表现活跃，截至发稿，乐普医疗股价涨停，报18.97元，换手率8.52%，成交额24.48亿元。消息面上，从国家药监局获悉，2025年我国已批准上市的创新药达76个，创历史新高。我国创新药对外授权交易总金额超过1300亿美元。医美业务则呈现产品与渠道双轮驱动态势。国盛证券最新研报指出，乐普医疗政策影响已逐步出清，医美等新业务处于快速放量期，创新业务将成为未来核心增长极。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/SS2026010500014424.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0251","BK0113","06978","BK1574","BK0028","BK0196","159992","BK1161","BK0114","BK0042","300003","BK0201","BK0188"],"gpt_icon":0},{"id":"2601079222","title":"异动快报：乐普医疗（300003）1月5日10点45分触及涨停板","url":"https://stock-news.laohu8.com/highlight/detail?id=2601079222","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601079222?lang=zh_cn&edition=full","pubTime":"2026-01-05 10:50","pubTimestamp":1767581429,"startTime":"0","endTime":"0","summary":"证券之星1月5日盘中消息，10点45分乐普医疗触及涨停板。其所属行业医疗器械目前上涨。领涨股为伟思医疗。该股为血氧仪，医疗器械，基因编辑概念热股，当日血氧仪概念上涨5.58%，医疗器械概念上涨4.37%，基因编辑概念上涨4.23%。12月31日的资金流向数据方面，主力资金净流出774.08万元，占总成交额3.72%，游资资金净流出136.86万元，占总成交额0.66%，散户资金净流入910.94万元，占总成交额4.38%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010500008552.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0196","BK0188","300003","BK0114","BK0042","BK0251","BK0113","BK0201","BK0028"],"gpt_icon":0},{"id":"2592193431","title":"童颜针价格战白热化 乐普医疗靠医美“救场”能否挽救传统业务颓势？","url":"https://stock-news.laohu8.com/highlight/detail?id=2592193431","media":"华夏时报网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592193431?lang=zh_cn&edition=full","pubTime":"2025-12-19 22:02","pubTimestamp":1766152920,"startTime":"0","endTime":"0","summary":" 对此，乐普医疗董秘表示：公司第三季度童颜针与水光针实现营业收入8613.67万元。今年由新氧发起的价格战，使得这款产品一再降价。 到2023年，已有5款童颜针产品上市销售。 造成这一趋势的根本原因在于公司赖以生存的传统业务遭遇政策性冲击。然而，其原料药业务大幅下滑26.89%。 未来，乐普医疗的传统业务能否扭转颓势，能否顺利化解商誉风险，《华夏时报》记者将会持续关注。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2025-12-19/doc-inhciyiz5560446.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2025-12-19/doc-inhciyiz5560446.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0251","BK0114","BK0113","BK0042","BK0201","BK0188","BK0196","300003","BK0028"],"gpt_icon":0},{"id":"2591702602","title":"乐普医疗：童颜针与水光针实现营业收入8613.67万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2591702602","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591702602?lang=zh_cn&edition=full","pubTime":"2025-12-16 16:51","pubTimestamp":1765875068,"startTime":"0","endTime":"0","summary":"证券之星消息，乐普医疗(300003)12月16日在投资者关系平台上答复投资者关心的问题。投资者提问：国内获批的9款童颜针产品，每一款都有自己的“独门绝技”，在市场上各显神通，请问董秘，乐普的悦雅颜珍珠、逆龄从品牌影响力、产品质量、价格、市场推广等多个方面进行综合分析评估，累计销售数量目前达到多少支了，对营业收入、利润贡献多少？医美版块占公司业绩的占比有多少？乐普医疗回复：尊敬的投资者，您好！公司第三季度童颜针与水光针实现营业收入8613.67万元，感谢您的关心。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121600026452.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300003"],"gpt_icon":0},{"id":"2591022406","title":"乐普医疗：不向下修正“乐普转2”转股价格","url":"https://stock-news.laohu8.com/highlight/detail?id=2591022406","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591022406?lang=zh_cn&edition=full","pubTime":"2025-12-16 16:45","pubTimestamp":1765874714,"startTime":"0","endTime":"0","summary":"证券之星消息，乐普医疗12月16日在投资者关系平台上答复投资者关心的问题。公司于2025年12月5日发布《关于不向下修正“乐普转2”转股价格的公告》，公司董事会决定本次不向下修正“乐普转2”转股价格，且自董事会审议通过次日起至“乐普转2”存续期结束，如再次触发“乐普转2”转股价格向下修正条款，亦不提出向下修正方案。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121600025798.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","300003","BK0201","BK0114","BK0188","BK0196","BK0042","BK0251","BK0113"],"gpt_icon":0},{"id":"2591602616","title":"乐普医疗：截至目前未持有君实生物股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2591602616","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591602616?lang=zh_cn&edition=full","pubTime":"2025-12-16 16:36","pubTimestamp":1765874181,"startTime":"0","endTime":"0","summary":"证券之星消息，乐普医疗(300003)12月16日在投资者关系平台上答复投资者关心的问题。投资者提问：公司及其关联方持有多少君实生物股份？谢谢乐普医疗回复：尊敬的投资者，您好！截至目前，本公司及关联方并未持有任何君实生物（股票代码：01877.HK/688180.SH）的股份。感谢您的关心。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121600024809.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300003","BK0028","BK0196","BK1161","688180","BK0114","BK1583","BK1515","BK0188","BK0042","BK0201","BK0251","BK0239","BK0113","01877"],"gpt_icon":0},{"id":"2589895006","title":"乐普医疗董事会决定不向下修正“乐普转2”转股价格","url":"https://stock-news.laohu8.com/highlight/detail?id=2589895006","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589895006?lang=zh_cn&edition=full","pubTime":"2025-12-05 18:19","pubTimestamp":1764929958,"startTime":"0","endTime":"0","summary":"中访网数据 乐普(北京)医疗器械股份有限公司于2025年12月5日召开第六届董事会第十九次会议，审议通过了《关于不向下修正“乐普转2”转股价格》的议案。此外，董事会进一步决议，自2025年12月6日起至“乐普转2”存续期结束，在此期间内即使再次触发向下修正条款，公司亦将不提出转股价格向下修正方案。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/ggzixun/20251205/31847618.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK0042","BK0028","BK0188","BK0251","BK0114","BK0201","BK0113","300003","BK0196"],"gpt_icon":0},{"id":"2588725643","title":"乐普医疗（300003）披露关于预计触发乐普转2转股价格向下修正条件的提示性公告，12月1日股价上涨0.38%","url":"https://stock-news.laohu8.com/highlight/detail?id=2588725643","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588725643?lang=zh_cn&edition=full","pubTime":"2025-12-01 17:53","pubTimestamp":1764582791,"startTime":"0","endTime":"0","summary":"截至2025年12月1日收盘，乐普医疗报收于16.0元，较前一交易日上涨0.38%，最新总市值为294.94亿元。该股当日开盘15.94元，最高16.01元，最低15.81元，成交额达2.53亿元，换手率为1.01%。公司近日发布公告称，自2025年11月16日至11月28日，公司股票已有10个交易日收盘价低于当期转股价格27.86元/股的80%，预计触发“乐普转2”转股价格向下修正条件。若触发修正条件，公司将于当日召开董事会审议是否修正转股价格，并及时履行信息披露义务。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120100023328.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0114","BK0251","300003","BK0188","BK0042","BK0196","BK0201","BK0113","BK0028"],"gpt_icon":0},{"id":"2586020682","title":"乐普生物-B(02157)与乐普医疗订立CDMO服务框架协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2586020682","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586020682?lang=zh_cn&edition=full","pubTime":"2025-11-28 16:48","pubTimestamp":1764319714,"startTime":"0","endTime":"0","summary":"智通财经APP讯，乐普生物-B(02157)发布公告，于2025年11月28日，本公司与乐普医疗订立CDMO服务框架协议，本公司及/或其附属公司同意向乐普医疗及/或其附属公司提供CDMO技术服务。考虑到本集团为满足自身临床试验及商业化而对药物生产的需求之外，本集团可在适当的商机出现时更有效利用富余产能。董事认为，订立CDMO服务框架协议将能更有效利用本集团的富余产能，可为本集团整体产生补充现金流量。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1375068.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0042","BK0188","BK0113","BK0196","BK0028","BK0201","BK4139","BK0114","CDMO","BK1161","300003","02157","BK0251"],"gpt_icon":0},{"id":"2581775105","title":"乐普医疗（300003）披露召开2025年第二次临时股东大会提示性公告，11月05日股价上涨3.35%","url":"https://stock-news.laohu8.com/highlight/detail?id=2581775105","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2581775105?lang=zh_cn&edition=full","pubTime":"2025-11-05 22:16","pubTimestamp":1762352197,"startTime":"0","endTime":"0","summary":"截至2025年11月5日收盘，乐普医疗报收于17.88元，较前一交易日上涨3.35%，最新总市值为329.6亿元。该股当日开盘17.83元，最高18.38元，最低17.6元，成交额达10.15亿元，换手率为3.57%。公司近日发布公告称，乐普（北京）医疗器械股份有限公司将于2025年11月10日14:30召开2025年第二次临时股东大会，会议采取现场与网络投票相结合方式。中小投资者表决结果将单独计票并披露。现场会议登记时间为2025年11月6日至7日，可通过现场、信函、电子邮件或传真方式登记。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110500040640.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300003","BK0188","BK0251","BK0042","BK0114","BK0028","BK0201","BK0113","BK0196"],"gpt_icon":0},{"id":"2580786532","title":"乐普医疗跌4.95% 中国银河等3券商年内高点唱多","url":"https://stock-news.laohu8.com/highlight/detail?id=2580786532","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2580786532?lang=zh_cn&edition=full","pubTime":"2025-11-04 17:20","pubTimestamp":1762248021,"startTime":"0","endTime":"0","summary":"中国经济网北京11月4日讯 乐普医疗 今日收报17.30元，跌幅4.95%。 乐普医疗股价8月25日盘中创下年内最高点21.18元。 中国银河证券股份有限公司研究员程培、孟熙8月25日发布研报《乐普医疗：创新及消费双轮驱动 业绩持续修复回升》称，维持乐普医疗“推荐”评级。 华泰证券股份有限公司研究员代雯、高鹏、杨昌源8月25日发布研报《乐普医疗：2Q业绩增长提速 长期业务看点丰富》称，维持乐普医疗“买入”。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushijujiao/20251104/31766198.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK0251","BK0114","06881","BK0042","BK0113","BK1564","BK0276","601881","BK0201","BK0188","BK0196","300003","BK0028","BK1147"],"gpt_icon":0},{"id":"2580200330","title":"乐普医疗(300003.SZ)：可充电植入式脑深部神经刺激器系统产品获注册批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2580200330","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2580200330?lang=zh_cn&edition=full","pubTime":"2025-11-04 16:06","pubTimestamp":1762243571,"startTime":"0","endTime":"0","summary":"智通财经APP讯，乐普医疗 公告，公司控股子公司乐普医学电子仪器股份有限公司自主研发的可充电植入式脑深部神经刺激器、植入式脑深部神经刺激电极组件、植入式脑深部神经刺激延伸导线套件获得国家药品监督管理局注册批准。可充电植入式脑深部神经刺激器系统产品的成功获批上市是公司在神经调控领域的重要成果，有利于公司布局神经调控领域，为帕金森病患者提供了新的治疗产品。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1364982.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"乐普医疗(300003.SZ)：可充电植入式脑深部神经刺激器系统产品获注册批准","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0188","BK0251","BK0028","300003","BK0113","BK0201","BK0114","BK0042","BK0196"],"gpt_icon":0},{"id":"2580298599","title":"乐普医疗（300003）披露可转债转股价格调整公告，11月03日股价上涨0.28%","url":"https://stock-news.laohu8.com/highlight/detail?id=2580298599","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2580298599?lang=zh_cn&edition=full","pubTime":"2025-11-03 17:20","pubTimestamp":1762161618,"startTime":"0","endTime":"0","summary":"截至2025年11月3日收盘，乐普医疗报收于18.2元，较前一交易日上涨0.28%，最新总市值为335.5亿元。该股当日开盘19.07元，最高19.35元，最低18.14元，成交额达12.91亿元，换手率为4.41%。公司近日发布公告称，因注销回购股份37,215,700股，占总股本1.9789%，导致公司股份变动，根据《募集说明书》及相关规定，对可转换公司债券“乐普转2”的转股价格进行调整。本次转股价格调整依据相关公式计算，调整后的转股价格自2025年11月3日起生效。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110300023335.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0251","BK0028","300003","BK0113","BK0201","BK0114","BK0042","BK0196"],"gpt_icon":0},{"id":"2580414986","title":"乐普医疗公布国际专利申请：“一种PPG信号血糖预测模型的处理方法和装置”","url":"https://stock-news.laohu8.com/highlight/detail?id=2580414986","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2580414986?lang=zh_cn&edition=full","pubTime":"2025-11-01 05:49","pubTimestamp":1761947388,"startTime":"0","endTime":"0","summary":"证券之星消息，根据企查查数据显示乐普医疗（300003）公布了一项国际专利申请，专利名为“一种PPG信号血糖预测模型的处理方法和装置”，专利申请号为PCT/CN2024/140883，国际公布日为2025年10月30日。专利详情如下：图片来源：世界知识产权组织（WIPO）今年以来乐普医疗已公布的国际专利申请1个。结合公司2025年中报财务数据，今年上半年公司在研发方面投入了3.95亿元，同比增10.89%。数据来源：企查查以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110100004829.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0251","300003","BK0113","BK0188","BK0028","BK0201","BK0114","BK0042","BK0196"],"gpt_icon":0},{"id":"2579754464","title":"乐普医疗最新公告：子公司与丹麦Sidera签署授权许可协议获9.99%股权及累计不超过10.1亿美元里程碑付款","url":"https://stock-news.laohu8.com/highlight/detail?id=2579754464","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579754464?lang=zh_cn&edition=full","pubTime":"2025-10-31 20:49","pubTimestamp":1761914957,"startTime":"0","endTime":"0","summary":"乐普医疗公告称，公司旗下上海民为生物与丹麦Sidera签署协议，上海民为生物将MWN105注射液的全球开发和商业化独家权利授予丹麦Sidera，作为对价，上海民为生物将获得丹麦Sidera公司9.99%的股权，并有权收取累计不超过10.1亿美元的里程碑付款。同时，上海民为生物将从丹麦Sidera获得销售提成。该协议有助于推动公司GLP-1多靶点药物的全球布局，提升国际竞争力。但药品研发及上市存在不确定性，里程碑付款金额也存在不确定性。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025103100047120.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300003","BK0114","BK0196","BK0113","BK0201","BK0028","BK0042","BK0188","BK0251"],"gpt_icon":0},{"id":"2578051556","title":"乐普医疗：医美产品进展及布局影响","url":"https://stock-news.laohu8.com/highlight/detail?id=2578051556","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2578051556?lang=zh_cn&edition=full","pubTime":"2025-10-28 08:45","pubTimestamp":1761612315,"startTime":"0","endTime":"0","summary":"证券之星消息，乐普医疗10月27日在投资者关系平台上答复投资者关心的问题。获批后对公司的业绩和医美版块的布局会产生哪些影响，对公司的业绩能带来多大的业绩？这些新产品的陆续上市将进一步完善公司医美产品矩阵，为业务发展注入新动能。产品实际销售情况将受到宏观经济环境、市场竞争格局、监管政策等多重因素影响，具体业绩表现请以公司后续披露的财务报告为准。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102800009715.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0196","BK0251","BK0114","BK0188","300003","BK0042","BK0028","BK0201","BK0113"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1768157855073,"stockEarnings":[{"period":"1week","weight":0.2302},{"period":"1month","weight":0.2436},{"period":"3month","weight":0.1159},{"period":"6month","weight":0.3178},{"period":"1year","weight":0.8582},{"period":"ytd","weight":0.2302}],"compareEarnings":[{"period":"1week","weight":0.0382},{"period":"1month","weight":0.0564},{"period":"3month","weight":0.0573},{"period":"6month","weight":0.1739},{"period":"1year","weight":0.2831},{"period":"ytd","weight":0.0382}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"乐普(北京)医疗器械股份有限公司","boardCode":"AI0035","boardName":"专用设备制造业","stockholders":"82918人(较上一季度减少17.13%)","perCapita":"19041股","listingDate":"2009-10-30","address":"北京市昌平区超前路37号","registeredCapital":"184339万元","survey":" 乐普(北京)医疗器械股份有限公司的主营业务是提供心血管疾病领域全生命周期的整体解决方案。公司的主要产品是医疗器械、药品、医疗服务、健康管理。截至报告期末，公司累计申请专利2,374项，国家药品监督管理局注册批准的II、III类医疗器械注册证687个，美国FDA认证34项，欧盟CE认证214项。","listedPrice":29},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"乐普医疗(300003)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供乐普医疗(300003)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"乐普医疗,300003,乐普医疗股票,乐普医疗股票老虎,乐普医疗股票老虎国际,乐普医疗行情,乐普医疗股票行情,乐普医疗股价,乐普医疗股市,乐普医疗股票价格,乐普医疗股票交易,乐普医疗股票购买,乐普医疗股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"乐普医疗(300003)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供乐普医疗(300003)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}